<DOC>
	<DOCNO>NCT01766154</DOCNO>
	<brief_summary>The purpose study evaluate tirofiban concentration blood period 24 hour tirofiban administration . Subjects vary degree renal insufficiency ( i.e . kidney function ) include study . Tirofiban know clear blood kidney people kidney problem clear tirofiban slow extent compare people without kidney problem . By compare tirofiban concentration profile subject healthy kidney function versus impair kidney function , tirofiban dose recommendation subject impair kidney function make . This non-randomized , single-center , open-label study . A single dose tirofiban ( 25 µg/kg administer intravenously 3 min period ) administer subject normal renal function ( &gt; 90 mL/min CrCl ) , moderate ( 30-59 mL/min CrCl ) , severe ( &lt; 30 mL/min CrCl ) renal impairment non-dialysis-dependent renal insufficiency</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Tirofiban Using Single High-Dose Bolus In Subjects With Varying Degrees Renal Function</brief_title>
	<detailed_description>Tirofiban clear plasma largely renal excretion . As consequence , dosage adjustment 50 % tirofiban label dose regimen ( 0.4 μg/kg/min period 30 minute , follow infusion 0.10 μg/kg/min ) recommend patient severe renal impairment ( &lt; 30 mL/min CrCl ) , include require hemodialysis . The dosage adjustment tirofiban high-dose bolus regimen ( 25 μg/kg bolus follow 0.15 μg/kg/min maintenance ) patient vary degree renal insufficiency however unknown . The purpose study determine extent dosage adjustment high-dose bolus regimen patient moderate ( 30-59 mL/min CrCl ) , severe ( &lt; 30 mL/min CrCl ) renal insufficiency . This non-randomized , single-center , open-label study evaluate pharmacokinetic ( PK ) , pharmacodynamic ( PD ) , safety profile single high-dose IV bolus injection tirofiban ( 25 µg/kg ) . A single dose tirofiban administer subject normal renal function ( &gt; 90 mL/min CrCl ) , moderate ( 30-59 mL/min CrCl ) , severe ( &lt; 30 mL/min CrCl ) renal impairment non-dialysis-dependent renal insufficiency ( NDDRI ) .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>1 . Male female 1885 year age . The mean age subject normal renal function ( CrCl &gt; 90 mL/min ) match mean age subject moderate severe renal impairment ( CrCl 3059 mL/min , CrCl &lt; 30 mL/min ) . 2 . BMI ≥18.5 ≤32.0 . 3 . Subjects able willing provide inform consent . 1 . Taking medication Prohibited Medication List . 2 . Active pericarditis . 3 . Presumed documented history vasculitis . 4 . Uncontrolled hypertension ( blood pressure &gt; 180/110 mm Hg ) . 5 . Dependency renal dialysis . 6 . Active internal bleeding bleed diathesis , surgery , trauma gastrointestinal/genitourinary tract bleed within 6 week prior dose . 7 . Prior intracranial hemorrhage , hemorrhagic stroke , cerebrovascular accident ( CVA ) within 2 year CVA significant residual neurological deficit , intracranial neoplasm , arteriovenous malformation , intracranial aneurysm , intracranial structural abnormality . 8 . Thrombocytopenia ( platelet count &lt; 100 x 10³ µL ) history thrombocytopenia follow heparin , tirofiban , eptifibatide administration . 9 . Taking OvertheCounter ( OTC ) vitamins and/or herbal supplement include garlic oil supplement , fish oil supplement , ginger supplement onion extract pill within 14 day dose . 10 . Participation another clinical trial 30 day prior participation current study . 11 . Any condition opinion Investigator may compromise safety compliance subject would preclude subject successfully complete trial . 12 . Female subject positive pregnancy test Screening Admission ( Day 1 ) , breastfeed . 13 . Inability comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>tirofiban</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>Phase 1</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>